At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 27 enrolled
Drug / intervention
YF476 +1 moredrug
Likely dose
YF476 25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized Placebo-Controlled Trial of YF476, a Gastrin Receptor Antagonist, in Barrett's Esophagus
In Brief
A Phase 2 clinical trial evaluating YF476 and Placebo for Barrett's Esophagus. Completed, enrolled 27 participants across 2 sites in 2 countries.
Detailed Summary
The purpose of this study is to determine whether treatment with an experimental drug called YF476 in patients with Barrett's esophagus reduces the expression of tissue markers that are associated with an increased risk of developing esophageal cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBarrett's Esophagus
CountriesUnited Kingdom, United States
CollaboratorsTrio Medicines Ltd.
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJun 2010
First PostedFeb 2011
Primary CompletionDec 2017
TodayJul 2026
First PostedFeb 18, 2011
Enrollment StartJun 1, 2010
Primary CompletionDec 1, 2017
TodayJul 2, 2026
Enrollment to primary: 7.5 yearsPosted 15.4 years ago
Interventions
YF476drug
25 mg: one capsule to be taken by mouth once daily for 12 weeks.
Placebodrug
Matching placebo: one capsule to be taken by mouth once daily for 12 weeks.